Modulation of Apoptosis by IRF-4 in EBV transformation

IRF-4 在 EBV 转化中对细胞凋亡的调节

基本信息

  • 批准号:
    7756516
  • 负责人:
  • 金额:
    $ 27.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-04 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

Epstein-Barr virus (EBV) infection is an important cause of lymphomas in AIDS patients, especially in central nervous system lymphoma (CNS lymphoma). EBV transforms human primary B cells in vitro, the process of which is believed to resemble EBV transformation in vivo in AIDS-associated CNS lymphoma. How EBV regulates cellular genes to achieve the transformation remains unclear. Interferon regulatory factor-4 (IRF-4) is a member of the IRF family that has oncogenic potential. IRF-4 is highly expressed in EBV-transformed primary B cells in vitro, and high IRF-4 expression is associated with EBV in primary CNS lymphomas. Furthermore, down-regulation of IRF-4 results in apoptosis in EBV-transformed cells, and restore the IRF-4 expression prevented the growth inhibition of endogenous IRF4-kncokdown cells. Thus, IRF-4 is a critical factor involved in EBV-transformation, and a potential therapeutic target for EBV-associated tumors in vivo; however, the anti-apoptotic mechanism of IRF-4 in EBV transformation is unknown. Our long-term goal is to understand the role of cellular factors in viral transformation. The more immediate goal of this application is to determine the anti-apoptotic mechanisms of IRF-4 in EBV-transformed B lymphocytes. Apoptosis is roughly classified as intrinsic and extrinsic pathways. EBV induces some anti-apoptotic Bcl-2 family members that are capable of prevention of the intrinsic apoptosis pathway, and uses several viral proteins to block the functions of p53, a potential intrinsic pathway inducer. We thus hypothesize that an intrinsic apoptosis pathway may be activated but blocked by IRF-4 during EBV transformation. We will determine the mitochondria integrity and some hallmark caspase activities after IRF-4-knockdown to distinguish the two pathways. Whether specific inhibitors of caspases and other critical molecules involved in apoptosis rescue IRF-4-knockdown cells from apoptosis will be examined. These experiments may identify the apoptosis. These experiments may identify critical mechanisms that IRF-4 uses to prevent apoptosis in EBV-transformed cells.
EB病毒(Epstein-Barr Virus,EBV)感染是艾滋病患者发生淋巴瘤的重要原因,尤其是中枢神经系统淋巴瘤。EBV在体外转化人原代B细胞,其过程被认为类似于艾滋病相关中枢神经系统淋巴瘤体内EBV转化。EBV如何调节细胞基因以实现转化尚不清楚。干扰素调节因子-4(IRF-4)是IRF家族中具有致癌潜能的成员。在体外EBV转化的原代B细胞中,IRF-4高表达,在原发性中枢神经系统淋巴瘤中,IRF-4的高表达与EBV相关。此外,下调IRF-4导致EBV转化细胞的凋亡,恢复IRF-4的表达可阻止内源性IRF4-Kncokdown细胞的生长抑制。因此,IRF-4是EBV转化过程中的一个关键因子,也是EBV相关肿瘤体内潜在的治疗靶点;然而,IRF-4在EBV转化中的抗凋亡机制尚不清楚。我们的长期目标是了解细胞因子在病毒转化中的作用。这项应用的更直接的目标是确定IRF-4在EBV转化的B淋巴细胞中的抗凋亡机制。细胞凋亡大致分为内源性和外源性两种途径。EBV可诱导一些抗凋亡的Bcl2家族成员,这些成员能够阻止固有的细胞凋亡途径,并利用多种病毒蛋白阻断潜在的内在途径诱导物P53的功能。因此,我们推测,在EBV转化过程中,IRF-4可能激活并阻断了一条内在的凋亡途径。我们将检测IRF-4基因敲除后线粒体的完整性和一些标志性的caspase活性,以区分这两条途径。是否特定的半胱氨酸天冬氨酸酶的抑制剂和其他关键分子参与的凋亡拯救IRF-4基因敲除细胞的凋亡将被检测。这些实验可能会鉴定细胞的凋亡。这些实验可能确定IRF-4用来防止EBV转化细胞凋亡的关键机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LUWEN ZHANG其他文献

LUWEN ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LUWEN ZHANG', 18)}}的其他基金

Interferon Regulatory Factor 7 and NPC
干扰素调节因子 7 和 NPC
  • 批准号:
    7022909
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    6919516
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    7369791
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    7032430
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    7844530
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Interferon Regulatory Factor 7 and NPC
干扰素调节因子 7 和 NPC
  • 批准号:
    6852445
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
HERPES VIRUS AND CELL INTERACTIONS
疱疹病毒和细胞的相互作用
  • 批准号:
    7170375
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    7578939
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
Oncogenic properties of interferon regulatory factor 7
干扰素调节因子 7 的致癌特性
  • 批准号:
    7217942
  • 财政年份:
    2005
  • 资助金额:
    $ 27.29万
  • 项目类别:
HERPES VIRUS AND CELL INTERACTIONS
疱疹病毒和细胞的相互作用
  • 批准号:
    7011816
  • 财政年份:
    2004
  • 资助金额:
    $ 27.29万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了